Dacomitinib (Dacomitinib) Medical Insurance Price Analysis

Dacomitinib (Dacomitinib), a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for non-small cell lung cancer (NSCLC), developed by Pfizer It was developed and approved by the U.S. Food and Drug Administration (FDA) in 2018, specifically for the treatment of patients with metastatic non-small cell lung cancer with EGFR mutations.

The good news for Chinese patients is that Dacomitinib is now available in China and has been included in the medical insurance catalog. Patients can purchase it at domestic hospital pharmacies. Its specifications are 15 mg and 30 pills, and the price is relatively affordable, about more than a thousand yuan. For specific price information and medical insurance reimbursement policies, patients are advised to consult their local hospital pharmacy to obtain the latest and most accurate information. In comparison, the price of Pfizer's original drug in the European market is relatively expensive, about more than 20,000 yuan. In foreign markets, the price is relatively more affordable for generic drugs produced in Laos. Its specifications are 45mg30 tablets. The price is only about one-third of the domestic price, and its drug ingredients are basically the same as the original drugs, providing patients with more choices.

Dacomitinib has a unique mechanism of action. It can irreversibly bind and inhibit the tyrosine kinase activity of EGFR, thereby effectively blocking the activation of the EGFR signaling pathway. EGFR signaling pathway plays a key role in the growth and spread of many cancers, especially in NSCLC. Common EGFR mutations include L858R point mutations and exon 19 deletions. These mutations will lead to the continued activation of the EGFR signaling pathway, thereby promoting the proliferation and survival of cancer cells. Dacomitinib (Dacomitinib) effectively inhibits these mutant EGFR and thus exerts a powerful anti-tumor effect.

InARCHER 1050clinical trials,Dacomitinib was compared head-to-head with the first-generation EGFR-TKI gefitinib (Gefitinib ). The study results showed that dacomitinib (dacomitinib) performed well in prolonging the progression-free survival (PFS) of patients, with the median PFS reaching 14.7 months, while gefitinib was only 9.2 months. In addition, Dacomitinib also showed a certain overall survival (OS) advantage. However, it is worth noting that the use of dacomitinib is also associated with a higher incidence of adverse reactions, including rash, diarrhea, stomatitis, and nail lesions. Therefore, clinicians need to closely monitor and appropriately manage patients when using dacomitinib (dacomitinib) to ensure that patients can safely and effectively benefit from this innovative drug.